Molecular Underpinnings of Severe Coronavirus Disease 2019.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Genetic Screening forFrontiers in immunology · 2021
   Trial
2. Update on human genetic susceptibility to COVID-19: susceptibility to virus and response.Human genomics · 2021
   Article
3. Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies.American journal of physiology. Lung cellular and molecular physiology · 2021
   Review
4. Genetic mechanisms of critical illness in COVID-19.Nature · 2021
   Article
5. Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment.Dermatology (Basel, Switzerland) · 2021
   Review
6. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?Frontiers in physiology · 2020
   Review

Corrections and comments

• Comment on
  Presence of Genetic Variants Among Young Men With Severe COVID-19.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as